

## News Release

### **Biofrontera announces brokerage agreement and research coverage with finnCap**

Leverkusen, Germany, 6 September 2013 – Biofrontera AG (B8F) announces today that it is now working with with the London based investment bank finnCap regarding the brokerage of Biofrontera shares. FinnCap's renowned life science analyst Dr. Keith Redpath has initiated coverage of Biofrontera, and will follow the company in the future.

**For further information please contact:**

Anke zur Mühlen  
Corporate Communication

+ 49 (0) 214 87632 22  
+ 49 (0) 214 87632 90  
a.zurmuehlen@biofrontera.com

Biofrontera AG  
Hemmelrather Weg 201  
D- 51377 Leverkusen, Germany

FinnCap is an independent UK investment house, with an excellent track record in the financing of small and medium-sized companies. Extending the investor relations activities towards institutional investors in London and the initiation of research coverage by finnCap is a consequent step towards the internationalization of Biofrontera AG.

#### **Biofrontera AG**

Biofrontera aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection.

Biofrontera AG is listed on the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN number DE0006046113.

*www.biofrontera.com*